Bio-Techne Q4 Preview: NIH Funding Cut And Tariffs Impacts, Initiate At Sell

An analyst initiates a 'Sell' rating on Bio-Techne (NASDAQ:TECH) with a fair value of $48 per share, citing the stock's significant overvaluation at over 38x FY26 free cash flow. While the company is a market leader in biological reagents, well-positioned for long-term growth in cell and gene therapies due to recurring consumables revenue and tailwinds like FDA changes favoring organoids, near-term risks temper the outlook. These include potential NIH funding cuts impacting 6% of revenue and an estimated $20 million impact on operating profits from U.S.-China tariffs, leading to a cautious FY26 organic growth projection of 4.8% compared to 6% in FY25, despite strong Q3 FY25 results.

Analysis

Bio-Techne Corporation (TECH) exhibits a fundamental dichotomy between its strong long-term market position and significant near-term risks that appear under-priced by the market. The company is a leader in life science reagents with over 70% of revenue from its Protein Sciences segment and a resilient model where approximately 80% of revenue is from recurring consumables. This positions it well to capitalize on secular growth trends, notably the cell and gene therapy market, which is forecast to grow at a 24% CAGR through 2034. Strategic moves, such as the 19.9% investment in Wilson Wolf and tailwinds from FDA policy changes favoring organoid solutions, further bolster this long-term outlook. Recent performance underscores this strength, with Q3 FY25 results showing 6% organic revenue growth and a 190 basis point expansion in adjusted operating margin. However, this positive backdrop is contrasted by considerable headwinds and a demanding valuation. The stock trades at over 38x FY26 free cash flow, a significant premium to the analyst's DCF-derived fair value of $48 per share. Key risks include proposed NIH funding cuts, which place 6% of Bio-Techne's total revenue at risk, and an estimated $20 million operating profit impact from U.S.-China tariffs. These factors are expected to suppress FY26 organic growth to 4.8% and pressure near-term margins.

Key Decisions for Investors

• Given the stock is trading at a significant premium of over 38x FY26 free cash flow relative to a $48 fair value estimate, investors should reassess their positions due to the substantial valuation risk.
• Closely monitor political developments concerning the proposed NIH budget cuts for 2026 and management's progress on mitigating the $20 million tariff impact, as these are the primary catalysts for the anticipated cautious FY26 outlook.
• Pay specific attention to the company's forward-looking guidance in its upcoming Q4 FY25 earnings release on August 6th, as confirmation of a weaker growth forecast could trigger a stock price correction.